Phase 1/2Recruiting
Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma
A Phase Ib/II Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma
- Sponsor
- Evopoint Biosciences Inc. (Industry)
- Enrolment
- 176 planned
- Conditions
- Non-hodgkin Lymphoma; Peripheral T-cell Lymphoma
- Interventions
- XNW5004 combined with CHOP (incremental); XNW5004 combined with CHOEP (incremental); XNW5004 combined with CHOP (extended); XNW5004 combined with CHOEP (extended)
- Ages
- adults, older adults
- Registry
- NCT07730515
Full record on ClinicalTrials.gov
From the registry
In this study, the XNW5004 tablets combined with CHOP/CHOEP will be used for the treatment of newly diagnosed PTCL patients.
Primary outcomes
- Ib/II:Incidence and severity of treatment-emergent adverse events (AEs) [Safety and Tolerability].
- II：Objective response rate (ORR)
- Ib:Maximum tolerated dose (MTD) and/or the recommended Part 2 dose
History
Primary completion expected
Last registry update
Registered
Started